Smaller institutions have the advantage of being more agile and adaptable. They can quickly pivot their research focus in response to emerging trends or novel hypotheses. This agility allows them to explore unconventional or high-risk ideas that larger institutions might overlook. Moreover, they often focus on rare cancers or unique aspects of cancer biology, contributing valuable insights to the overall understanding of the disease.
